• Featured Product
  • KD/KO Validated

SUCLG2 Polyclonal antibody

SUCLG2 Polyclonal Antibody for IHC, IP, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IP, IHC, IF, ELISA

Conjugate

Unconjugated

Cat no : 14240-1-AP

Synonyms

G BETA, SCS betaG, SUCLG2



Tested Applications

Positive WB detected inCOLO 320 cells, HepG2 cells, mouse liver tissue, rat liver tissue
Positive IP detected inmouse kidney tissue
Positive IHC detected inhuman colon cancer tissue, human gliomas tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:5000-1:50000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC)IHC : 1:250-1:1000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Product Information

14240-1-AP targets SUCLG2 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, mouse, rat samples.

Tested Reactivity human, mouse, rat
Cited Reactivityhuman
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen SUCLG2 fusion protein Ag5495
Full Name succinate-CoA ligase, GDP-forming, beta subunit
Calculated Molecular Weight 47 kDa
Observed Molecular Weight 47 kDa
GenBank Accession NumberBC047024
Gene Symbol SUCLG2
Gene ID (NCBI) 8801
RRIDAB_2197187
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

Background Information

SUCLG2, encodes a GTP-specific beta subunit of succinyl-CoA synthetase. Succinyl-CoA synthetase catalyzes the reversible reaction involving the formation of succinyl-CoA and succinate. The deficiency of SUCLG2 represents an encephalomyopathic form of mtDNA depletion syndromes (PMID:30470562). Mutated SUCLG1 causes mislocalization of SUCLG2 protein, morphological alterations of mitochondria and an early-onset severe neurometabolic disorder. SUCLG2 is mainly expressed in liver, kidney, heart (PMID: 9765291).

Protocols

Product Specific Protocols
WB protocol for SUCLG2 antibody 14240-1-APDownload protocol
IHC protocol for SUCLG2 antibody 14240-1-APDownload protocol
IP protocol for SUCLG2 antibody 14240-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Oncogene

Pharmacologically targetable vulnerability in prostate cancer carrying RB1-SUCLA2 deletion.

Authors - Susumu Kohno
  • KO Validated
humanWB,IHC,IF,IP

Adv Sci (Weinh)

SUCLG2 Regulates Mitochondrial Dysfunction through Succinylation in Lung Adenocarcinoma

Authors - Qifan Hu